Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2023 Results Conference Call May 4, 2023 8:45 AM ET

Company Participants

Lisa Caperelli - VP of IR

Bill Collier - President, CEO and Director

David Hastings - CFO and CAO

Karen Sims - VP of Clinical Development

Michael Sofia - Chief Scientific Officer

Conference Call Participants

Thomas Yip - H.C. Wainwright

Roy Buchanan - JMP

Dennis Ding - Jefferies

Operator

Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2023 First Quarter Financial Results and Corporate Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, VP of Investor Relations, Lisa Caperelli. Please go ahead.

Lisa Caperelli

Thank you, Elenor. Good morning, everyone, and thank you for joining Arbutus' first quarter 2023 financial results and corporate update call. Joining me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; David Hastings, Chief Financial Officer; Dr. Mike Sofia, Chief Scientific Officer; and Dr. Karen Sims, VP of Clinical Development. Bill will begin with a corporate update, followed by Dave Hastings who will then provide a review of the company's first quarter 2023 financial results. After our prepared remarks, we will open the call for Q&A. Doctors Sofia and Sims will be available to address your clinical and scientific questions.

Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, which are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our most recent annual report on Form 10-K, our quarterly report on Form 10-Q, which will be filed later today and from time to time in our other documents filed with the SEC.

With that, I'll now turn the call over to Bill Collier. Bill?

Bill Collier

Thank you, Lisa, and good morning, everyone, and thank you very much for joining us today.

Now Arbutus was founded with the goal of developing a functional cure for patients with chronic hepatitis B virus by advancing the development of our clinical and preclinical assets that could be combined to create a treatment regimen. At the onset of the COVID-19 pandemic in 2020, we made the strategic decision to leverage our team of virologists and their expertise in discovering, developing and commercializing antiviral compounds to expand our core focus to include developing treatment options for COVID-19 as well as future coronavirus outbreaks. With our expanded focus on pipeline, our Arbutus today is actively advancing a broad portfolio of innovative clinical candidates that address large market opportunities.